Heart:不同抗血小板治疗与经皮冠状动脉介入治疗死亡率之间的关系!

2018-02-03 xing.T MedSci原创

由此可见,在89000名接受PCI的STEMI患者队列中,相比于氯吡格雷和替卡格雷,普拉格雷可以显著降低30天和1年死亡率。

与氯吡格雷相比,普拉格雷和替卡格雷可以减少急性冠脉综合征高危人群的缺血性终点事件。然而,在经皮冠状动脉介入治疗(PCI)的ST段抬高型心肌梗死(STEMI)患者采用两种新药治疗的比较结局尚不明确。近日,在心脏病领域权威杂志Heart上发表了一篇研究文章,研究人员试图通过接受直接PCI的STEMI患者的英国心血管介入学会全国数据库来分析这个问题。

研究人员比较从2007年1月到2014年12月期间采用P2Y12抗血小板药物治疗的超过89000例接受PCI治疗的患者数据。统计模型,包括倾向匹配、多元logistic回归(MLR)和比例风险模型,被用来研究不同抗血小板药物使用与全因死亡率之间的关系。

主要MLR分析结果显示,普拉格雷与氯吡格雷相比,可以显著降低PCI术后30天死亡率(比值比为0.87,95%可信区间为0.78-0.97,P=0.014)和1年死亡率(比值比为0.89、95%可信区间为0.82-0.97,P=0.011)。替卡格雷相比于氯吡格雷在30天死亡率(比值比为1.07,95%可信区间为0.95-1.21,P=0.237)或1年死亡率(比值比为1.058、95%可信区间为0.96-1.16,P=0.247)没有任何显著差异。最后,替卡格雷在这两个时间点的死亡率明显高普拉格雷(30 天死亡率比值比为1.22、95%可信区间为1.03-1.44,P=0.020;1 年死亡率比值比为为1.19、95%可信区间为1.04-1.35,P=0.01)。

由此可见,在89000名接受PCI的STEMI患者队列中,相比于氯吡格雷和替卡格雷,普拉格雷可以显著降低30天和1年死亡率。

原始出处:


Ivan Olier,et al. Association of different antiplatelet therapies with mortality after primary percutaneous coronary intervention. Heart. 2018. http://dx.doi.org/10.1136/heartjnl-2017-312366

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1648933, encodeId=5a3716489336b, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Nov 26 05:02:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285503, encodeId=59362855036e, content=受教了., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8sYHCPqtn0aUWywsfKibdCUbJOTrGuwSt8ryEbSChJ7SXJvDCzUR91FVEicCFW0PClAs1vYDiajqYw/132, createdBy=6f5c2263960, createdName=Blank_, createdTime=Tue Feb 06 00:19:47 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320745, encodeId=b4341320e4559, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356670, encodeId=58af13566e001, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562818, encodeId=41db15628187d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284794, encodeId=3890284e9489, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sat Feb 03 18:39:42 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1648933, encodeId=5a3716489336b, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Nov 26 05:02:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285503, encodeId=59362855036e, content=受教了., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8sYHCPqtn0aUWywsfKibdCUbJOTrGuwSt8ryEbSChJ7SXJvDCzUR91FVEicCFW0PClAs1vYDiajqYw/132, createdBy=6f5c2263960, createdName=Blank_, createdTime=Tue Feb 06 00:19:47 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320745, encodeId=b4341320e4559, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356670, encodeId=58af13566e001, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562818, encodeId=41db15628187d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284794, encodeId=3890284e9489, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sat Feb 03 18:39:42 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-06 Blank_

    受教了.

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1648933, encodeId=5a3716489336b, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Nov 26 05:02:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285503, encodeId=59362855036e, content=受教了., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8sYHCPqtn0aUWywsfKibdCUbJOTrGuwSt8ryEbSChJ7SXJvDCzUR91FVEicCFW0PClAs1vYDiajqYw/132, createdBy=6f5c2263960, createdName=Blank_, createdTime=Tue Feb 06 00:19:47 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320745, encodeId=b4341320e4559, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356670, encodeId=58af13566e001, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562818, encodeId=41db15628187d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284794, encodeId=3890284e9489, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sat Feb 03 18:39:42 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1648933, encodeId=5a3716489336b, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Nov 26 05:02:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285503, encodeId=59362855036e, content=受教了., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8sYHCPqtn0aUWywsfKibdCUbJOTrGuwSt8ryEbSChJ7SXJvDCzUR91FVEicCFW0PClAs1vYDiajqYw/132, createdBy=6f5c2263960, createdName=Blank_, createdTime=Tue Feb 06 00:19:47 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320745, encodeId=b4341320e4559, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356670, encodeId=58af13566e001, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562818, encodeId=41db15628187d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284794, encodeId=3890284e9489, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sat Feb 03 18:39:42 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-05 zhaojie88
  5. [GetPortalCommentsPageByObjectIdResponse(id=1648933, encodeId=5a3716489336b, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Nov 26 05:02:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285503, encodeId=59362855036e, content=受教了., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8sYHCPqtn0aUWywsfKibdCUbJOTrGuwSt8ryEbSChJ7SXJvDCzUR91FVEicCFW0PClAs1vYDiajqYw/132, createdBy=6f5c2263960, createdName=Blank_, createdTime=Tue Feb 06 00:19:47 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320745, encodeId=b4341320e4559, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356670, encodeId=58af13566e001, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562818, encodeId=41db15628187d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284794, encodeId=3890284e9489, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sat Feb 03 18:39:42 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-05 slcumt
  6. [GetPortalCommentsPageByObjectIdResponse(id=1648933, encodeId=5a3716489336b, content=<a href='/topic/show?id=6e0630843d0' target=_blank style='color:#2F92EE;'>#冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30843, encryptionId=6e0630843d0, topicName=冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a9ec23698107, createdName=3631181, createdTime=Mon Nov 26 05:02:00 CST 2018, time=2018-11-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=285503, encodeId=59362855036e, content=受教了., beContent=null, objectType=article, channel=null, level=null, likeNumber=68, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/DYAIOgq83er8sYHCPqtn0aUWywsfKibdCUbJOTrGuwSt8ryEbSChJ7SXJvDCzUR91FVEicCFW0PClAs1vYDiajqYw/132, createdBy=6f5c2263960, createdName=Blank_, createdTime=Tue Feb 06 00:19:47 CST 2018, time=2018-02-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1320745, encodeId=b4341320e4559, content=<a href='/topic/show?id=cd29e838938' target=_blank style='color:#2F92EE;'>#经皮冠状动脉介入治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=78389, encryptionId=cd29e838938, topicName=经皮冠状动脉介入治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec19483, createdName=aids213, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1356670, encodeId=58af13566e001, content=<a href='/topic/show?id=b0702e84b9' target=_blank style='color:#2F92EE;'>#ART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=2784, encryptionId=b0702e84b9, topicName=ART)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1562818, encodeId=41db15628187d, content=<a href='/topic/show?id=f69d864413' target=_blank style='color:#2F92EE;'>#HEART#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8644, encryptionId=f69d864413, topicName=HEART)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=80d715270048, createdName=slcumt, createdTime=Mon Feb 05 04:02:00 CST 2018, time=2018-02-05, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=284794, encodeId=3890284e9489, content=学习一下谢谢, beContent=null, objectType=article, channel=null, level=null, likeNumber=56, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/mONcle9pic3zSn0GqHrsfLGSUSR8zwnWWLT4FMl5XH8S58HuZslVkLsAPbXDXaliagK7TOxQfmngKibG1yrDonepCLDkcxGk8hS/0, createdBy=b8282062892, createdName=changjiu, createdTime=Sat Feb 03 18:39:42 CST 2018, time=2018-02-03, status=1, ipAttribution=)]
    2018-02-03 changjiu

    学习一下谢谢

    0

相关资讯

基因检测 排除氯吡格雷抵抗

65岁的张先生有吸烟史,4个月前因发作胸骨后烧灼样疼痛,就诊于当地医院。经检查,考虑冠状动脉粥样硬化性心脏病,急性下壁心肌梗死,心功能Ⅰ级。

Circ-Cardiovasc Inte:氯吡格雷治疗对心脑血管疾病患者死亡率和癌症的影响!

由此可见,在心血管和脑血管疾病的试验中,在服用阿司匹林的基础上延长氯吡格雷治疗对死亡率和癌症发生整体上没有影响,但确实降低了心肌梗死和卒中的发生率,并增加了出血的发生率。这些研究结果强调有选择性地对那些缺血风险不能被出血风险完全抵消的患者延长氯吡格雷治疗。

Int J Cardiol:急性冠状动脉综合征患者从氯吡格雷转换为普拉格雷对早期侵入性治疗的影响!

由此可见,将NSTE-ACS患者PCI前转换为普拉格雷60或30 mg治疗比继续使用氯吡格雷要更好更快地进行血小板抑制。

AHA2017:真实世界数据挑战临床试验结果:新型P2Y12抑制剂真的优于氯吡格雷?

P2Y12抑制剂作为急性冠脉综合征(ACS)患者抗血小板治疗的基石药物,关于其药物选择问题一直备受关注。

J Am Heart Assoc:吸烟/不吸烟的行PCI的ACS患者:双倍剂量vs标准剂量氯吡格雷

2017年11月,发表在《J Am Heart Assoc》的一项由加拿大、瑞士、美国等国科学家进行的研究比较了行经皮冠状动脉介入(PCI)的急性冠脉综合征(ACS)患者中,根据吸烟状态的双倍剂量和标准剂量氯吡格雷的效果。

Lancet:急性脑缺血的抗血小板治疗

研究发现,对于新发脑缺血患者,三联抗血小板强化治疗不能降低中风复发风险,反而导致出血事件的频率和严重程度增加。常规临床中不应采用三联抗血小板治疗